REVIEW ON A ORAL FILM FOR THE TREAMENT OF MIGRAINE

Pharmacy

Patients suffering migraines accompanied by nausea, vomiting, and sensitivity to light and sound should be provided with an oral film of an anti-migraine medication to help remove their pain. These severe headaches are often recurrent and are particularly prevalent in women. While weekly occurrences are typical, they can also present once every few years or even less frequently. The duration of these headaches can range from a few hours to three days, depending on their intensity. Generally, morning headaches tend to affect just one side of the head, usually the side of the forehead. Such headaches can be extremely debilitating and are very frequently reported. These conditions comprise the leading causes of headaches, accounting for 95 percent or more of all complaints. Utilizing transdermal patch technology, mouth-dissolving films and oral film represent an innovative method of drug delivery. When a patient's tongue or any mucosal surface comes into contact with saliva, a thin film forms on the area, which quickly hydrates and adheres to the site of application. Upon swallowing, it rapidly breaks down and dissolves, allowing the medication to be absorbed through the oral mucosa. In contrast to traditional methods, these fast-dissolving films can be produced at a cost similar to that of standard tablets, making them an innovative and promising option for delivering anti-migraine medications in the treatment of migraines. Among the various methods of administration, the oral route is the most preferred by patients. Many pharmaceutical companies have focused their research efforts on creating effective oral dosage alternatives for children, the elderly, patients with adherence issues, or those suffering nausea. Advancements in the oral drug delivery field have transformed dosage forms from basic traditional tablets and capsules to modified-release versions, as well as oral disintegrating tablets, culminating in the latest innovation of oral films.

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.